POSTDOCTORAL POSITION IN CANCER IMMUNOTHERAPY

A postdoctoral position is available in the group headed by Santos Mañes at the Centro Nacional de Biotecnología (CNB/CSIC) in Madrid, Spain.

The candidate will work in a collaborative project within a multidisciplinary team, aiming to understand the role of specific extracellular matrix proteins in the activation and differentiation of T cells in the context of cancer. The project is funded by the Spanish Ministry of Science and Innovation and the Spanish Association Against Cancer (AECC) Foundation.

We are seeking for highly motivated and talented postdoctoral researchers, preferentially with a previous expertise in molecular immunology, lymphoid organ structure and function and cancer immunotherapy. The project will involve, among other objectives, the creation of conditional transgenic mice and the collaboration with clinical oncologists and pathologists for the analysis of gene expression using digital spatial profiling technology.

The position offers the opportunity for professional growth by working in an interactive and dynamic environment of translational and basic science research. The candidate will have also the opportunity to participate in the mentoring of master and PhD students.

Interested applicants should send a cover letter describing their past experience and interests, as well as their CV (including Educational Information) to: Santos Mañes, smanes@cnb.csic.es (phone: +34 915 854 840).

Latest publications:

- Mira et al. 2018. SOD3 improves the tumor response to chemotherapy by stabilizing endothelial HIF-2α. Nat Commun. 9(1):575
- Carmona-Rodríguez et al. 2020. SOD3 induces a HIF-2α-dependent program in endothelial cells that provides a selective signal for tumor infiltration by T cells. J Immunother Cancer. 8(1):e000432
- Martín-Leal et al. 2020. CCR5 deficiency impairs CD4 + T-cell memory responses and antigenic sensitivity through increased ceramide synthesis. EMBO J. 39(15):e104749
- Quintela-Fandino et al. 2020. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. Breast Cancer Res. 22(1):124